

The facts: CGMs are better for everyone

Better for people with T1D



Funding CGMs benefits New Zealanders with T1D

- Combining CGM and insulin pump technology adds 6 years of healthy life per person
- HbA1c levels fall from 69mmol/mol to 58mmol/mol with CGM usage
- Other OECD nations fund a choice of CGMs including the UK, Canada and Australia.

Better for the health system



Funding CGMs benefits the health system

- CGMs are effective AND cost-effective
- CGM cost effectiveness is estimated at \$5.6K per healthy life year (HLY) restored
- Recent Pharmac-funded therapies cost \$50k+ per HLY; WHO recommends anything less than \$75K/HLY.

Better for NZ



Funding CGMs benefits the economy

- An investment of \$26m p.a. in funding CGMs will return \$82m p.a. in economic growth, including \$27m p.a. in tax revenue*
- That's a 3.2X return on investment.

There are 20,000 people in NZ living with type 1 diabetes. That means they have 120,000 family members, friends, and colleagues. That's 1,700 per NZ electorate.

It's time. Let's get CGMs for NZ.

For more information email
Sandra at sbraithwaite@jdrf.org.nz

*Note: Excludes complication costs, uses NZD. Economic productivity = DALYs averted X GDP per capita; but excludes indirect benefits and multiplier effects. Data derives from T1D Index, www.t1dindex.org.